Atria Investments LLC Has $1.10 Million Position in Genmab A/S (NASDAQ:GMAB)

Atria Investments LLC cut its position in Genmab A/S (NASDAQ:GMABGet Rating) by 16.0% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 30,346 shares of the company’s stock after selling 5,765 shares during the quarter. Atria Investments LLC’s holdings in Genmab A/S were worth $1,098,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. DAVENPORT & Co LLC raised its position in shares of Genmab A/S by 2.1% in the 4th quarter. DAVENPORT & Co LLC now owns 15,439 shares of the company’s stock valued at $611,000 after buying an additional 322 shares in the last quarter. Wetherby Asset Management Inc. grew its holdings in shares of Genmab A/S by 2.6% during the 4th quarter. Wetherby Asset Management Inc. now owns 14,389 shares of the company’s stock valued at $569,000 after purchasing an additional 358 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Genmab A/S by 50.3% during the 4th quarter. Bessemer Group Inc. now owns 1,156 shares of the company’s stock valued at $46,000 after purchasing an additional 387 shares during the last quarter. Cim LLC grew its holdings in shares of Genmab A/S by 1.7% during the 1st quarter. Cim LLC now owns 27,994 shares of the company’s stock valued at $1,002,000 after purchasing an additional 465 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Genmab A/S by 9.3% during the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company’s stock valued at $219,000 after purchasing an additional 513 shares during the last quarter. 5.92% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $36.47 on Thursday. Genmab A/S has a 52-week low of $26.19 and a 52-week high of $49.07. The company’s 50 day moving average price is $31.78 and its 200-day moving average price is $33.36. The company has a market capitalization of $23.98 billion, a P/E ratio of 63.98, a price-to-earnings-growth ratio of 1.52 and a beta of 0.86.

Genmab A/S (NASDAQ:GMABGet Rating) last released its earnings results on Wednesday, May 11th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. Genmab A/S had a net margin of 26.34% and a return on equity of 10.90%. The company had revenue of $319.54 million for the quarter, compared to the consensus estimate of $304.16 million. Analysts forecast that Genmab A/S will post 0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

GMAB has been the topic of several research reports. Cowen initiated coverage on shares of Genmab A/S in a report on Monday, May 2nd. They set a “market perform” rating and a $38.00 price target on the stock. Morgan Stanley decreased their price target on shares of Genmab A/S to $29.00 and set an “underweight” rating on the stock in a report on Tuesday, May 17th. HC Wainwright boosted their target price on shares of Genmab A/S from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, July 20th. Cowen started coverage on shares of Genmab A/S in a report on Monday, May 2nd. They set a “market perform” rating on the stock. Finally, TheStreet lowered shares of Genmab A/S from a “b-” rating to a “c+” rating in a report on Monday, June 13th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $424.09.

Genmab A/S Company Profile

(Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMABGet Rating).



Receive News & Ratings for Genmab A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genmab A/S and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *